Over the past several years clinical trials of IDH protein inhibition have demonstrated promising response rates in relapsed-refractory AML and there are currently several small molecule inhibitors that have been approved by the FDA for the treatment of IDH1 (ivosidenib, olutasidenib) or IDH2 (enasidenib) mutant AML (Gruber et al., 2022). Here, IDH1 is linked to acute myeloid leukemia.